Ascendis Pharma (ASND) has released an update. Ascendis Pharma reported a revenue of €57.8 million in Q3 2024, driven by product launches and ...
Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...
Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a report published on Monday, Benzinga reports. They currently have a $170.00 ...
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...
Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Monday, setting a price target of $209, which is approximately 33.55% ...
Wedbush upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. ASND has been the topic of ...
On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...
The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ascendis Pharma, and Ultragenyx Pharmaceutical. According to TipRanks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback